Novartis AG ADR (NVS)
Novartis AG ADR (NVS) carries a ŷRobot AI score of 57 out of 100. The model's fair value estimate is $154.83, 2.8% above the last close of $150.62. The chart signal reads Hold.
| Metric | NVS |
|---|---|
| AI score | 57 / 100 |
| Chart signal | Hold |
| Fair value estimate | $154.83 |
| Upside to fair value | 2.8% |
| Previous close | $150.62 |
| P/E | 22.04 |
| Price / sales | 4.73 |
| Market cap | $279.18B |
| EPS | 6.47 |
| Revenue growth | 8.0% |
| 1-year price change | 12.4% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, AstraZeneca PLC.
Questions about NVS
Is NVS overvalued or undervalued right now?
As of Oct 16, 2026, ŷRobot's fair-value model estimates Novartis AG ADR (NVS) at $154.83 against a last close of $150.62, implying 2.8% upside to the model's estimate.
Is NVS's chart signal bullish or bearish?
The chart-signal model classifies NVS as Neutral as of Oct 16, 2026, with a signal score of 0.01 on a -1 to 1 scale.
What is NVS's ŷRobot AI score?
NVS scores 57 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 16, 2026.
Is NVS stock expensive on P/E and P/S?
NVS trades at 22.0 times earnings and 4.7 times sales as of Oct 16, 2026.
What does NVS's seasonal forecast show?
ŷRobot's seasonal forecast curve for NVS reads +0.9% at 30 days, +5.3% at 90 days, and +12.4% at one year as of Oct 16, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is NVS growing?
Novartis AG ADR's revenue growth is +8.0% and free-cash-flow growth is +0.5% on the latest reported figures.
NVS chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.